NF Trinity Capital’s Edwards Lifesciences EW Stock Holding History

NF Trinity Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-168,243	Closed	-$5.28M	–	50
2017 Q1	$5.28M	Buy	+168,243	New	+$5.27M	0.71%	30

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

NF Trinity Capital's EW Position: Q2 2017 in Review

NF Trinity Capital sold out of Edwards Lifesciences (EW) in Q2 2017, closing a stake of 168,243 shares — an estimated $5.28M sold.

NF Trinity Capital first reported a position in EW in Q1 2017 and held it in 1 quarter. The position peaked at $5.28M in Q1 2017. 720 funds tracked by Wall St. Rank hold EW as of Q2 2017.

NF Trinity Capital reported no remaining Edwards Lifesciences position as of Q2 2017 after selling out during the quarter.
NF Trinity Capital sold 168,243 Edwards Lifesciences shares in Q2 2017, an estimated $5.28M.
NF Trinity Capital first reported a position in Edwards Lifesciences in Q1 2017 and held it in 1 quarter.
NF Trinity Capital's Edwards Lifesciences position peaked at $5.28M in Q1 2017.
720 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2017.

Based on NF Trinity Capital's 13F filing for Q2 2017, filed 8 Aug 2017.